^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-15 superagonist

    Related drugs:
    11d
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, University of Utah | Trial completion date: Sep 2031 --> Dec 2031 | Trial primary completion date: Sep 2030 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    13d
    FLINN: First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Washington University School of Medicine
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Anktiva (nogapendekin alfa inbakicept-pmln)
    26d
    A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Recruiting, Suzhou Forlong Biotechnology Co., Ltd | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    26d
    A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Suzhou Forlong Biotechnology Co., Ltd | Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    27d
    First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study (clinicaltrials.gov)
    P1, N=18, Completed, Suzhou Forlong Biotechnology Co., Ltd | Recruiting --> Completed | Trial completion date: Sep 2026 --> Sep 2025 | Trial primary completion date: May 2026 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    2ms
    3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803) (clinicaltrials.gov)
    P1, N=28, Active, not recruiting, Rockefeller University | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=328, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Oct 2025 --> May 2026
    Trial completion date
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK • aldoxorubicin (INNO-206)
    2ms
    N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy (clinicaltrials.gov)
    P1, N=8, Not yet recruiting, Northwestern University
    New P1 trial
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P1/2, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2028 --> Oct 2030 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Zynyz (retifanlimab-dlwr) • SX-682 • Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    CARMEN-803: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, University of Utah | Initiation date: Sep 2025 --> Dec 2025
    Trial initiation date
    |
    Anktiva (nogapendekin alfa inbakicept-pmln)
    3ms
    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=34, Recruiting, ImmunityBio, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    4ms
    Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, ImmunityBio, Inc. | Trial completion date: May 2029 --> Nov 2029 | Initiation date: May 2025 --> Nov 2025 | Trial primary completion date: May 2026 --> Nov 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    gemcitabine • Anktiva (nogapendekin alfa inbakicept-pmln)